VIRGINIA RETIREMENT SYSTEMS ET Al Purchases New Shares in Hims & Hers Health, Inc. $HIMS

Key Points

• Virginia Retirement Systems acquired a new stake in Hims & Hers Health, purchasing 25,400 shares valued at approximately $1,266,000 in the second quarter.
• In total, 63.52% of Hims & Hers Health's stock is owned by institutional investors, highlighting significant interest from larger financial entities.
• An analyst downgrade from Zacks Research changed Hims & Hers Health's rating from "strong-buy" to "hold", reflecting caution among analysts despite the company's strong revenue growth.

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 25,400 shares of the company's stock, valued at approximately $1,266,000.

Several other institutional investors have also added to or reduced their stakes in HIMS. Nuveen LLC bought a new stake in Hims & Hers Health in the 1st quarter valued at $58,403,000. Yong Rong HK Asset Management Ltd lifted its position in shares of Hims & Hers Health by 41.2% during the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock valued at $70,920,000 after acquiring an additional 700,100 shares during the period. CloudAlpha Capital Management Limited Hong Kong bought a new stake in shares of Hims & Hers Health during the 1st quarter valued at $20,580,000. Jump Financial LLC lifted its position in shares of Hims & Hers Health by 633.2% during the 1st quarter. Jump Financial LLC now owns 725,445 shares of the company's stock valued at $21,437,000 after acquiring an additional 626,496 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Hims & Hers Health by 19.5% during the 1st quarter. Northern Trust Corp now owns 2,435,512 shares of the company's stock valued at $71,969,000 after acquiring an additional 397,310 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,592 shares of the company's stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $57.13, for a total value of $662,250.96. Following the sale, the chief financial officer owned 70,232 shares in the company, valued at approximately $4,012,354.16. The trade was a 14.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Patrick Harrison Carroll sold 10,021 shares of the company's stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total value of $506,060.50. Following the completion of the sale, the insider owned 169,940 shares in the company, valued at $8,581,970. This trade represents a 5.57% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,432,206 shares of company stock worth $74,248,448. 13.71% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Zacks Research downgraded Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Weiss Ratings reissued a "hold (c+)" rating on shares of Hims & Hers Health in a report on Tuesday, October 14th. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. KeyCorp assumed coverage on Hims & Hers Health in a report on Tuesday. They set a "sector weight" rating for the company. Finally, Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of "Reduce" and a consensus target price of $38.92.

Hims & Hers Health Trading Down 3.9%

Shares of HIMS stock opened at $47.45 on Thursday. The firm has a market capitalization of $10.72 billion, a P/E ratio of 59.31, a P/E/G ratio of 3.42 and a beta of 2.25. Hims & Hers Health, Inc. has a twelve month low of $18.33 and a twelve month high of $72.98. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The stock's fifty day simple moving average is $51.05 and its 200 day simple moving average is $49.20.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company's revenue was up 72.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.